GlassScriptPhysician profile
Danielle Francis
NPI 1336119551
$10,669.92
in general payments reported to CMS, 2019-2025
50 companies · $408 in 2025
The $408 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,291 · 2022: $3,219 · 2023: $2,659 · 2024: $2,093 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,950 · Education: $210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,949.94 |
| Education | $209.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $1,474.61 | 2022-2023 | Pyrukynd |
| Astrazeneca Pharmaceuticals LP | $1,164.65 | 2021-2024 | Calquence, Imfinzi, Tagrisso |
| E.R. Squibb & Sons, L.L.C. | $667.93 | 2021-2025 | Opdivo, Opdualag |
| Seagen INC. | $631.44 | 2021-2023 | Tukysa, Padcev, Adcetris |
| Novartis Pharmaceuticals Corporation | $606.29 | 2022-2025 | |
| Amgen INC. | $570.21 | 2021-2023 | Nplate, Lumakras, Xgeva |
| Beigene USA, INC. | $380.75 | 2023-2024 | Brukinsa |
| Merck Sharp & Dohme LLC | $376.12 | 2021-2024 | Keytruda, Lynparza |
| Celgene Corporation | $365.56 | 2021-2025 | Pomalyst, Reblozyl |
| Janssen Biotech, INC. | $332.94 | 2021-2024 | Darzalex, Tecvayli, Imbruvica |
| Bayer Healthcare Pharmaceuticals INC. | $276.20 | 2021-2024 | |
| Gilead Sciences, INC. | $274.36 | 2022-2024 | Trodelvy |
| Pfizer INC. | $252.92 | 2021-2024 | |
| Incyte Corporation | $243.78 | 2021-2025 | Jakafi, Monjuvi |
| Pharmacyclics LLC, An Abbvie Company | $231.96 | 2021-2023 | Imbruvica |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epizyme, INC. | $212.31 | 2021-2022 | |
| Daiichi Sankyo INC. | $194.99 | 2022-2025 | Enhertu |
| Cti Biopharma Corp. | $181.94 | 2022-2023 | Vonjo |
| Regeneron Healthcare Solutions, INC. | $174.78 | 2021-2024 | Libtayo |
| G1 Therapeutics, INC. | $159.01 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $150.28 | 2022-2024 | |
| Exelixis INC. | $135.00 | 2021 | |
| Taiho Oncology, INC. | $131.84 | 2024 | |
| Biomarin Pharmaceutical INC. | $124.97 | 2024 | Roctavian |
| Lilly USA, LLC | $124.93 | 2023-2024 | Jaypirca, Verzenio, Retevmo |
| Genzyme Corporation | $124.87 | 2021-2025 | |
| Springworks Therapeutics, INC. | $120.92 | 2024 | Ogsiveo |
| Eisai INC. | $119.08 | 2021-2024 | |
| Aveo Pharmaceuticals, INC. | $118.16 | 2023-2025 | Fotivda |
| Adc Therapeutics America, INC. | $89.19 | 2021 | |
| Abbvie INC. | $81.50 | 2022-2025 | |
| Csl Behring | $64.02 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.65 | 2022-2023 | Iclusig, Alunbrig |
| Array Biopharma INC | $52.22 | 2021-2023 | Lorbrena, Braftovi, Mektovi |
| Rigel Pharmaceuticals, INC. | $50.81 | 2022-2024 | Rezlidhia, Tavalisse |
| Deciphera Pharmaceuticals INC. | $48.26 | 2021-2024 | Qinlock, Tgct |
| Astellas Pharma US INC | $43.04 | 2021-2022 | |
| Dova Pharmaceuticals | $41.87 | 2021 | |
| Puma Biotechnology, INC. | $38.20 | 2021-2022 | |
| Pharmacosmos Therapeutics INC. | $23.45 | 2024 | Cosela |
| Foundation Medicine, INC. | $19.45 | 2023 | |
| Morphosys, US INC. | $19.06 | 2023 | Monjuvi |
| Acrotech Biopharma INC. | $18.03 | 2022 | |
| Eusa Pharma (US) LLC | $17.78 | 2021 | |
| Clovis Oncology, INC. | $16.33 | 2021 | |
| Kite Pharma, INC. | $16.25 | 2022 | |
| Sobi, INC | $16.09 | 2024 | |
| Sumitomo Pharma America, INC. | $13.47 | 2023 | Orgovyx |
| Ge Healthcare | $9.41 | 2021 | |
| Heron Therapeutics, INC. | $9.04 | 2021-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Francis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.